The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer

被引:3
|
作者
Goktas Aydin, Sabin [1 ]
Bilici, Ahmet [1 ]
Olmez, Omer Fatih [1 ]
Oven, Basak B. B. [2 ]
Acikgoz, Ozgur [1 ]
Cakir, Tansel [3 ]
Basim, Pelin [4 ]
Cakir, Asli [5 ]
Kutlu, Yasin [1 ]
Hamdard, Jamshid [1 ]
机构
[1] Istanbul Medipol Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey
[2] Bahcesehir Univ, Med Fac, Dept Med Oncol, Istanbul, Turkey
[3] Istanbul Medipol Univ, Med Fac, Dept Nucl Med, Istanbul, Turkey
[4] Istanbul Medipol Univ, Med Fac, Dept Surg, Istanbul, Turkey
[5] Istanbul Medipol Univ, Med Fac, Dept Pathol, Istanbul, Turkey
关键词
Neoadjuvant chemotherapy; 18F-FDG PET; CT; Prognostic factors; Survival; Breast cancer; COMPLETE PATHOLOGICAL RESPONSE; F-18-FDG PET/CT; CHEMOTHERAPY; CRITERIA; THERAPY; MRI;
D O I
10.1159/000524446
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Patients with locally advanced breast cancer (LABC) should be treated with neoadjuvant chemotherapy (NAC). Pathological complete response (pCR) is related to better disease-free survival (DFS). The best strategy for assessing the efficacy of NAC has not been established yet, but several studies have shown that 18F-FDG PET/CT is a potential imaging tool for assessing pCR. The aim of this study is to investigate the merits of 18F-FDG PET/CT imaging in predicting pCR in both axillary and breast tissue and to establish a threshold maximum standard uptake value (SUVmax) for predicting the response after completion of NAC. Methods: A total of 186 LABC patients, treated with an NAC regimen according to tumor subtype, were retrospectively analyzed in this study. All patients underwent 18F-FDG PET/CT imaging before and after completion of NAC. PET parameters were measured in the most FDG avid breast tissue and axillary lymph nodes. We analyzed the correlation between the tumor SUVmax of the PET/CT response and the pCR after surgery. DFS was also evaluated with respect to pCR. Results: Higher pCR rates were significantly associated with a higher tumor grade, an initial Ki-67 >= 20% (p = 0.03 and p = 0.003, respectively), a triple-negative subtype (32.9%), and a human epidermal growth factor receptor 2 (HER-2)-positive subtype (24.7%) (p < 0.001). There was a significant correlation between the pCR and a complete response in 18F-FDG PET/CT (p < 0.001). The overall sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of 18F-FDG PET/CT to determine the pCR after NAC were 100%, 72.2%, 85%, 75.2%, and 100%, respectively. We demonstrated a 1.1 cutoff SUVmax for breast tumors after NAC (OR: 3.94, 95% CI: 1.14-5.05, p = 0.004), the 18F-FDG PET/CT response to NAC (OR: 0.50, 95% CI: 0.25-0.99, p = 0.003), and the molecular subtype of breast tumors (OR: 0.58, 95% CI: 0.38-0.88, p = 0.011). Conclusion: Our results confirm that 18F-FDG PET/CT is a useful method for predicting the NAC response in LABC.
引用
收藏
页码:470 / 479
页数:10
相关论文
共 50 条
  • [31] Concerning pretreatment 18F-FDG PET/CT imaging in patients with large or locally advanced breast cancer
    David Groheux
    Elif Hindié
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 1801 - 1803
  • [32] Concerning pretreatment 18F-FDG PET/CT imaging in patients with large or locally advanced breast cancer
    Groheux, David
    Hindie, Elif
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (12) : 1801 - 1803
  • [33] Textural analysis of baseline 18F-FDG PET for predicting treatment response and prognosis in patients with locally advanced esophageal cancer
    Sun, X.
    Sun, L.
    Xing, L.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S265 - S265
  • [34] 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
    Joan Duch
    David Fuster
    Montserrat Muñoz
    Pedro Luís Fernández
    Pilar Paredes
    Montserrat Fontanillas
    Flavia Guzmán
    Sebastià Rubí
    Francisco Juan Lomeña
    Francesca Pons
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36 : 1551 - 1557
  • [35] 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer
    Duch, Joan
    Fuster, David
    Munoz, Montserrat
    Luis Fernandez, Pedro
    Paredes, Pilar
    Fontanillas, Montserrat
    Guzman, Flavia
    Rubi, Sebastia
    Juan Lomena, Francisco
    Pons, Francesca
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (10) : 1551 - 1557
  • [36] 18F-FDG PET for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer
    Junichi, Hasegawa
    Hideaki, Miwa
    Ryohei, Kawabata
    Shingo, Noura
    Junzo, Shimizu
    Junichi, Nishimura
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [37] The utility of 18F-FDG PET/CT for monitoring of neoadjuvant therapy response in breast cancer
    Xing, W.
    Li, Q.
    Jiang, C.
    Chen, B.
    Sun, Y.
    [J]. BREAST, 2019, 44 : S76 - S77
  • [38] Usefulness of the 18F-FDG PET/CT in the Initial Staging of Locally Advanced Breast Cancer (LABC) Prior to Neoadjuvant Chemotherapy
    Sampol, C.
    Pozo, A.
    Torrecabota, J.
    Avella, T.
    Canet, R.
    Lopez, A.
    Rubi, S.
    Villar, M.
    Gimenez, M.
    Pena, C.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S358 - S358
  • [39] Can post neoadjuvant chemotherapy 18F-FDG PET/CT predict residual cancer burden in locally advanced breast cancer?
    Topuz, O. Vural
    Akkurt, T. S.
    Erdem, G. U.
    Kaya, E. M.
    Kaya, M.
    Akkas, B. E.
    [J]. MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2024, 48 (03): : 141 - 149
  • [40] 18F-FDG PET/CT in locally advanced cervical cancer: A review
    Caresia-Aroztegui, A. P.
    Delgado-Bolton, R. C.
    Alvarez-Ruiz, S.
    Del Puig Cozar-Santiago, M.
    Orcajo-Rincon, J.
    de Arcocha-Torres, M.
    Garcia-Velloso, M. J.
    [J]. REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2019, 38 (01): : 59 - 68